Kadmon Holdings, Inc.

Robbins LLP Is Investigating the Officers and Directors of Kadmon Holdings, Inc. (KDMN) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Kadmon Holdings, Inc. (NYSE: KDMN) violated federal securities laws in connection with the company's "co-promotion" relationship with Valeant Pharmaceuticals, whose former employees were charged with fraud in November 2016. Kadmon, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases.

Kadmon Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.

Skip to content